Evidence map›Paper›PMID 39883942›Full record

ArticleBlood advances2025

A model of zymogen factor XII: insights into protease activation.

Aleksandr Shamanaev, Yujie Ma, Michal B Ponczek, Mao-Fu Sun, Quifang Cheng, S Kent Dickeson, Owen J T McCarty, Jonas Emsley, Bassem M Mohammed, David Gailani

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. A brief comparison of human factor XII-AlaResearch and practice in thrombosis and haemostasis · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aleksandr ShamanaevDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2348-1444
Yujie MaBiodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.ORCID 0009-0001-6533-0284
Michal B PonczekDepartment of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.ORCID 0000-0002-0839-8004
Mao-Fu SunDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-0662-1409
Quifang ChengDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
S Kent DickesonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Owen J T McCartyDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-9481-0124
Jonas EmsleyBiodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0002-8949-8030
Bassem M MohammedDepartment of Biochemistry and Molecular Biology, Edward A. Doisy Research Center, St. Louis University School of Medicine, St. Louis, MO.ORCID 0000-0001-7227-3663
David GailaniDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-8142-8014

Funding

Biochemistry and Pathophysiology of Factor XI and Contact ActivationR35HL140025 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAILANI, DAVID · 2018 to 2024
$5.5M
NHLBI NIH HHS R35 HL140025
6 · The paper itself

Abstract

abstractIn plasma, the zymogens factor XII (FXII) and prekallikrein reciprocally convert each other to the proteases FXIIa and plasma kallikrein (PKa). PKa cleaves high-molecular-weight kininogen (HK) to release bradykinin, which contributes to regulation of blood vessel tone and permeability. Plasma FXII is normally in a "closed" conformation that limits activation by PKa. When FXII binds to a surface during contact activation it assumes an "open" conformation that increases the rate of activation by PKa. Mutations in FXII that disrupt the closed conformation have been identified in patients with conditions associated with excessive bradykinin formation. Using FXII structures from the AlphaFold database, we generated models for the closed form of human FXII that we tested with site-directed mutagenesis. The models predict multiple interactions between the fibronectin type 2 (FN2), kringle, and catalytic domains involving highly conserved amino acids that restrict access to the FXII activation cleavage sites. Based on the model, we expressed FXII with single-amino acid substitutions and studied their effects on FXII activation by PKa. Replacements for Arg36 in the FN2 domain; Glu225, Asp253, or Trp268 in the kringle domain; or Lys346 near the activation cleavage site were activated >10-fold faster by PKa than wild-type FXII. Adding these proteins to plasma resulted in rapid HK cleavage due to markedly enhanced reciprocal activation with prekallikrein. The results support a model that explains the behavior of FXII in solution. Conformational changes involving the identified amino acids likely occur when FXII binds to a surface to facilitate activation.

Indexed as

Factor XIIBradykininCatalytic DomainEnzyme ActivationHumansKininogen, High-Molecular-WeightModels, MolecularMutationPrekallikreinProtein BindingProtein ConformationBradykininFactor XIIKininogen, High-Molecular-WeightPrekallikrein

Identifiers

PMID39883942
PMCPMC12018978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.